The promotion of data sharing in pharmacoepidemiology by Sethi, Nayha
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Promotion of Data Sharing in Pharmacoepidemiology
Citation for published version:
Sethi, N 2014, 'The Promotion of Data Sharing in Pharmacoepidemiology' European Journal of Health Law,
vol 21, no. 3, pp. 271-96., 10.1163/15718093-12341323
Digital Object Identifier (DOI):
10.1163/15718093-12341323
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher final version (usually the publisher pdf)
Published In:
European Journal of Health Law
Publisher Rights Statement:
This is an open-access article distributed under the terms of the Creative Commons Attribution 3.0 Unported
(CC BY 3.0) License, http://creativecommons.org/licenses/by/3.0/
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 20. Feb. 2015
© Nayha Sethi, ���4 | doi �0.��63/�57�8093-��34�3�3 
This is an open-access article distributed under the terms of the Creative Commons Attribution 3.0 
Unported (CC BY 3.0) License, http://creativecommons.org/licenses/by/3.0/
european Journal of health law �� (�0�4) �7�-�96
brill.com/ejhl
 
 
The Promotion of Data Sharing in 
Pharmacoepidemiology
Nayha Sethi*
 Research Fellow, School of Law, University of Edinburgh, UK
Abstract 
This article addresses the role of pharmacoepidemiology in patient safety and the cru-
cial role of data sharing in ensuring that such activities occur. Against the backdrop of 
proposed reforms of European data protection legislation, it considers whether the cur-
rent legislative landscape adequately facilitates this essential data sharing. It is argued 
that rather than maximising and promoting the benefits of such activities by facili-
tating data sharing, current and proposed legislative landscapes hamper these vital 
activities. The article posits that current and proposed data protection approaches to 
pharmacoepidemiology — and more broadly, re-uses of data — should be reoriented 
towards enabling these important safety enhancing activities. Two potential solutions 
are offered: 1) a dedicated working party on data reuse for health research and 2) the 
introduction of new, dedicated legislation.
Keywords 
pharmacoepidemiology – secondary uses – data reuse – health research – data 
protection – data sharing
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1 Introduction
This article posits that a responsive, adaptable and flexible approach to data 
reuse for research is imperative for patient safety, and uses pharmacoepidemi-
ological research as a case-study to do so. Pharmacoepidemiological research 
provides an important case-study because it straddles the divide between 
traditional monitoring of patient safety, within pharmacovigilance and wider 
reuse of health data in the research setting, which also contributes signifi-
cantly towards ensuring patient safety. 
It is argued that current categorisations within the law of different con-
ditions of health data reuse present an artificial distinction between such 
interrelated activities. The article begins by considering pharmacoepide-
miology and the numerous benefits of the discipline in terms of enhancing 
patient safety. The crucial importance of patient data to these activities is high-
lighted. Self-evidently, the more accurate, complete and readily available these 
data are, the clearer the picture about medicine safety and efficacy becomes. 
Data protection legislation and the related obligations to which it gives rise 
play a fundamental role in determining whether access to data is granted and 
under which circumstances. Given the reliance on data and the proposed 
legislative changes to data protection legislation which are currently under 
consideration within the European Union, it is timely to consider whether 
the current legislative landscape adequately facilitates pharmacoepidemio-
logical activities and whether proposed changes will also do so, or change the 
dynamic for ill. 
It is argued here that rather than maximising the benefits of such activi-
ties by enabling sharing, the current and proposed legislative landscapes are 
unnecessarily inhibitive. This manifestly does not reflect the public interest 
in scientifically sound medical research and in ensuring patient safety. Nor 
does it appreciate the obstructive effects which arbitrary categorisation of 
data sharing activities can have. It is proposed here that the law can be framed 
so as to act as an enabler, and a cultural driver for sharing in appropriate cir-
cumstances. This does not denigrate the important role of the law in inhibit-
ing inappropriate data sharing, however a balance must be achieved, rather 
than the current status quo where data reuse is often prevented even in ethi-
cally and scientifically sound projects and despite the fact that patient safety 
stands to benefit. Responsive, adaptive and operationalisable solutions are 
required. Two options for improving the situation are briefly outlined: the 
first comes in the form of a dedicated working party tasked with consid-
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ering issues arising from reuse of health data for research; the second is a 
proposal for new legislative provision that specifically addresses data reuse 
for research. 
First, a preliminary note; reference is often made within the health research 
literature to ‘secondary uses of data’ this is to say, data ‘initially collected for 
another purpose’.1 While this might seem to be simply a matter of semantics, 
it is argued here that reference to the term ‘secondary uses’, is unhelpful and 
antithetical to one of the key messages in this article, viz, that such data reuses 
are valuable and merit due recognition and, when appropriate, prioritisation. 
The language that we use is all-important because the term ‘secondary use’ 
tends to imply ‘inferior’ use. A more helpful framing might be achieved via 
rephrasing ‘secondary uses’ of data to ‘data reuse’. Accordingly, the term ‘data 
reuse’ is used throughout this article. 
2 Pharmacoepidemiology: An Overview
This initial section considers the crucial role which pharmacoepidemiology 
plays in patient safety and why data access is key in facilitating such activities. 
First, however, a brief summary of what pharmacoepidemiology entails, and 
how it has developed since its emergence is offered.
2.1  What Is Pharmacoepidemiology?
Pharmacoepidemiology is ‘the study of the use, and effects, of drugs and other 
medical devices in large numbers of people’,2 ‘it aims to examine all detectable 
effects, whether beneficial or adverse’.3 It encompasses many activities includ-
ing the study of adverse drug reactions (ADRs). An adverse drug reaction is 
described as: 
1 W. Lowrance, “Learning from experience: privacy and the secondary use of data in health 
research”,  Journal of Health Services Research & Policy 8(2) (2003) 2-7.
2 B. Strom, S. Kimmel, S. Hennessy (Eds.), Textbook of Pharmacoepidemiology, second edition, 
(Chichester: Wiley, 2013) p. 3.
3 Prime Vigilance. 2014. Epidemiology and Pharmacoepidemiology in relation to Pharma-
covigi lance. Retrieved 16 January 2014, www.primevigilance.com/information-and-resources/ 
complexities-in-drug-safety/epidemiology-and-pharmacoepidemiology-in-relation- 
to-pharmacovigilance. 
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an unwanted or harmful reaction experienced following the administra-
tion of a drug or combination of drugs under normal conditions of use, 
which is suspected to be related to the drug. The reaction may be a known 
side effect of the drug or it may be new and previously unrecognised.4 
Pharmacoepidemiology is considered for present purposes, as the study of the 
use of effects of drugs amongst large populations after a drug has received its 
licence, in the post-marketing phase.5 
Few laws existed to regulate drug marketing and development at the time of 
the Thalidomide revelations6,7 and a clear need for addressing drug safety 
issues was identified, guidelines were developed across different countries in 
order to monitor drugs for ADRs. Examples include: the US Kefauver-Harris 
Amendments8 the UK Yellow Card Scheme9 and Directive 65/65/EEC to  safeguard 
public health concerning production and distribution of medicinal products.10 
4 Medicines and Healthcare products Regulatory Agency. 2013. “Information for healthcare 
professionals: Adverse drug reactions”. Retrieved 7 January 2014, www.mhra.gov.uk. 
5 Note that this distinction between the pre and post-marketing phase is important for the 
purposes of the present discussion because it is posited that pharmacoepidemiological 
studies, which involve the reuse of data and involve data linkage methods (considered 
further below) are important for patient safety but that they are not granted due impor-
tance within the legislative framework, in comparison with pre-marketing studies. This 
will become clearer in due course.
6 L. Härmark, A. C. van Grootheest, “Pharmacovigilance: methods, recent developments 
and future perspectives”, European Journal of Clinical Pharmacology 64 (2008) 743-752, 
at 745. 
7 Thalidomide was used to treat morning sickness in pregnant mothers and resulted in 
thousands of babies being born with congenital deformities. W. McBride, “Thalidomide 
and congenital malformations”, Lancet 2 (1961) 1358.
8 These amendments were made to the Food, Drug and Cosmetic Act in 1962. To ensure 
greater drug safety, drug manufacturers had to prove the efficacy of drugs prior to market-
ing. J. Greene and S. Podolsky, “Reform, Regulation and Pharmaceuticals — The Kefauver-
Harris Amendments at 50”, New England Journal of Medicine 367 (2012) 1481-1483.
9 L. Rägo and B. Santoso, “Drug Regulation: History, Present and Future” in: C. van Boxtel, 
B. Santoso and I. Edwards (eds.), Drug Benefits and Risks: International Textbook of Clinical 
Pharmacology, revised 2nd edition( IOS Press and Uppsala Monitoring Centre, 2008) 66.
10 Council Directive 65/65/EEC of 26 January 1965 on the approximation of provisions laid 
down by law, regulation or administrative action relating to medicinal products (OJ L No 
22 of 9. 2. 1965, p. 369). (As amended by Directives 66/454/EEC, 75/319/EEC, 83/570/EEC, 
87/21/EEC, 89/341/EEC 89/342/EEC 89/343/EEC, 92/27/EEC, 92/73/EEC et 93/39/EEC). 
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Subsequently, a plethora of legislation has emerged,11 rendering patient 
safety a core aspect of drug development and research. Numerous national 
level pharmacoepidemiology centres and coordinated research initiatives 
exist.12,13,14 Whilst drug surveillance has significantly enhanced patient safety, 
the prevalence and under-reporting of ADRs remains.15,16 
2.2  Why Is Pharmacoepidemiology so Important for Patient Safety? 
Pharmacoepidemiological studies are integral to patient safety, when a drug is 
available to the wider population and throughout the lifetime of each patient 
who consumes the medication. Studies affect other patients with similar ill-
nesses by influencing the availability of such drugs and the ability to make 
informed decisions about drug suitability given knowledge about patient 
experiences. Without pharmacoepidemiology, our understanding of the safety 
and efficacy of medicines is limited; such studies offer a much more complete 
picture about drugs and allow us to detect risks which would only appear 
11 With most recent legislative provisions including Directive 2010/84/EU amending, as 
regards pharmacovigilance, Directive 2001/83/EC and Regulation 1235/2010 amending, as 
regards pharmacovigilance, Regulation No. 726/2004.
12 See for example: The University of Manchester, “Centre for Pharmacoepidemiology and 
Drug Safety”. Retrieved 26 March 2014, www.pharmacy.manchester.ac.uk/cpds; Agencia 
Española de medicamentos y productos sanitaros (The Spanish Medicines Agency). 
Retrieved 26 March 2014, www.aemps.gob.es/en/home.htm; Agence nationale de sécurité 
du medicament et des produits de santé. Retrieved 26t March 2014, ansm.sante.fr/Declarer- 
un-effetindesirable/Pharmacovigilance/Organisation-de-la-pharmacovigilance-
nationale/(offset)/0. 
13 At a European level, the European Medicines Agency has established ENCePP (the European 
Network of Centres for Pharmacoepidemiology and Pharmacovigilance) ‘to further 
strengthen the post-authorisation monitoring of medicinal products in Europe’ European 
Network of Centres for Pharmacoepidemiology and Pharmacivigilance, “What is ENCePP?” 
2014. Retrieved 21 January 2014, www.encepp.eu/structure/index.shtml. 
14 A. Avery et al., ‘Evaluation of patient reporting of adverse drug reactions to the UK ‘Yellow 
Card Scheme’: literature review, descriptive and qualitative analyses, and questionnaire sur-
veys’ (2011) Technical Report: DOI: 10.3310/hta15200. NIHR HTA, Southampton. See also 
MHRA Yellow Card Scheme website. Retrieved 25 March 2014, yellowcard.mhra.gov.uk.
15 A. Sun et al., “Unplanned medication discontinuation as a potential pharmacovigilance sig-
nal: a nested young person cohort study”, BMC Pharmacology and Toxicology 15(11) (2014). 
16 Often, ADR detection is carried out through spontaneous reporting, discussed in 
more detail below, and commonly referred to as pharmacovigilance. Somewhat con-
fusingly, pharmacovigilance and pharmacoepidemiology are sometimes referred to 
interchangeably.
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when a large number of individuals have been exposed to a medicine. Clinical 
trials typically exclude or have limited involvement of certain population 
groups17,18,19,20 rendering extrapolation of results to these groups in the popu-
lation at large particularly difficult.21,22 Clinical trials traditionally occur over 
limited time periods. Pharmacoepidemiology enables us to monitor the effi-
ciency, effects and risks of a drug in the longer-term.23 We can also learn how 
drugs react with each other in patients with co-morbidities (also typically and 
routinely excluded from clinical trials).24 Pharmacoepidemiological studies 
can lead to withdrawal of a drug from the market and changes to the product 
label, indications for use and terms of availability.25 Additionally, such stud-
ies reveal unexpected benefits leading to use for treatment of diseases other 
than those for which the drug was originally developed, i.e., serendipitous drug 
discovery.26,27,28 
17 K. Shields and A. Lyerly, “Exclusion of pregnant women from industry-sponsored clinical 
trials”, Obstet Gynecol 122(5) (2013) 1077-1081.
18 F. Bourgeois et al., “Pediatric versus adult drug trials for conditions with high pediatric 
disease burden”, Pediatrics 130(2) (2012) 285-292. 
19 M. Murdo et al., “Improving recruitment of older people to research through good prac-
tice”, Age and Ageing 40(6) (2011) 659-665.
20 H. Van Spall et al., “Eligibility Criteria of Randomized Control Trials Published in High-
Impact General Medical Journals”, Journal of the American Medical Association 297(11) 
(2007) 1233-1240. 
21 Supra note 6. 
22 A. Heiat, C. Gross and H. Krumholz. “Representation of the Elderly, Women, and 
Minorities in Heart Failure Clinical Trials”, Archives of Internal Medicine 162(15) (2002) 
1682-1688.
23 See for example: S. Schneeweiss et al., “Admissions caused by adverse drug events to inter-
nal medicine and emergency departments in hospitals: a longitudinal population-based 
study”, European Journal of Clinical Pharmacology 58 (2002) 285-291; G. Niklas Noren and 
R. Edwards, “Modern methods of pharmacovigilance: detecting adverse effects of drugs”, 
Clinical Medicine 9(5) (2009) 486-489.
24 A. Jadad and T. Matthew, “Consideration of Multiple Chronic Diseases in Randomized 
Control Trials”, Journal of the American Medical Association 306(24) (2011). 
25 For example, from over the counter to prescription-only accessibility.
26 T. Ban, “The Role of Serendipity in Drug Discovery”, Dialogues Clinical Neuroscience 8(3) 
(2006) 335-344. 
27 T. Ashburn and K. Thor, “Drug repositioning: identifying and developing new uses for 
existing drugs”, National Review of Drug Discovery 3 (2004) 673-683; I. Goldstein et al., “Oral 
Sildenafil in the Treatment of Erectile Dysfunction”, New England Journal of Medicine 338 
(1998) 1397-1404. 
28 Ashburn and Thor, ibid.
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3  Data as a Key Component in Patient Safety
More accurate, accessible, and complete data offer more complete drug pro-
files which increase patient safety and facilitate the benefits of cost efficiency. 
Data sharing also plays a key role to ‘accelerate health improvements’ more 
generally.29 To fully appreciate the critical role which data play in enabling 
such activities, an overview of some methods and sources of data which phar-
macoepidemiological studies rely upon is helpful.
3.1  Spontaneous Reporting (SR)
Spontaneous Reporting (SR) is a flawed but essential tool used to flag ADRs.30 
In the UK, doctors are obliged to report ADRs31 and patients can report them 
via the Yellow Card Scheme,32 particularly important as prescribing for chil-
dren can often be off-label.33 Under-reporting of ADRs is problematic,34,35 due 
to failure to associate the ADR with the new drug36 or to understand when an 
ADR should be reported.37 This can be a challenge across the EU.38,39,40 Whilst 
29 B. Knoppers et al., “A human rights approach to an international code of conduct for 
genomic and clinical data sharing”, Human Genet (2014) (epub ahead of print). Retrieved 
31 March 2014, www.ncbi.nlm.nih.gov/pubmed/24573176. 
30 Indicated by the inverted black triangle symbol on the packet.
31 General Medical Council. 2013. “Good practice in prescribing and managing medicines 
and devices” 31 January 2013. Retrieved 8 April 2014, www.gmc uk.org/guidance/ethical_
guidance/14316.asp. 
32 The Medicines and Healthcare Products Regulatory Agency Yellow Card Scheme INSERT 
LINK.
33 See MHRA. 2014. “Black Triangle Scheme — new medicines and vaccines subject to EU-wide 
additional monitoring”. Retrieved 28 March 2014, www.mhra.gov.uk/Safetyinformation/
Howwemonitorthesafetyofproducts/Medicines/BlackTriangleproducts/index.htm. 
34 L. Hazell and S. Shakir, “Under-Reporting of Adverse Drug Reactions; A Systematic Review”, 
Drug Safety 29(5) (2006) 385-396.
35 Ibid., p. 394.
36 I. Eland, et al., “Attitudinal survey of voluntary reporting of adverse drug reactions”, 
Journal of Clinical Pharmacology 48(4) (1999) 623-627.
37 D. Williams and J. Feely, “Underreporting of adverse drug reactions: attitudes of Irish doctors”, 
Ir J Med Sci 168(1999) 257-261; M. Backstrom et al., “Attitudes to reporting adverse drug 
reactions in northern Sweden”, European Journal of Clinical Pharmacology 56 (2000) 729-732. 
38 Supra note 34. 
39 M. Herdeiro, “Physicians’ Attitudes and Adverse Drug Reaction Reporting”, Drug Safety 28 
(9) (2006) 825-833.
40 M. Bäckström, T. Mjörndal and R. Dahlqvist, “Under-reporting of serious adverse drug 
reactions in Sweden”, Pharmacoepidemiology and Drug Safety 13(7) (2004) 483-487.
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all ADRs must be reported for black triangle status drugs, for established drugs, 
only serious ADRs must be reported, leaving a significant gap in knowledge 
about more minor ADRs.41,42 SR ‘offers low evidence of risks associated with 
medicines’ but the ‘highest levels of uncertainty regarding causality’.43,44,45 If 
we are to achieve a reliable evidence base for serious and minor ADRs, and 
offer more certainty than that a drug is ‘apparently safe based on partial 
information’,46 then we must go well beyond SR.
3.2 Data Linkage (DL)
One method employed in pharmacoepidemiology, particularly significant 
here, is data linkage, which ‘. . . brings together information from two or more 
records from independent sources that are perceived to belong to the same 
individual, family, event or place’.47 DL relies upon reuse and linking of data 
sources such as: electronic health records; routinely collected administrative 
data such as prescribing data, hospital admissions, mortality and morbid-
ity data, cancer registries etc.48 Reusing data has many strengths, including 
that data are ‘collected prospectively without knowing the research question 
issues of bias.’49 DL provides a cost-effective means of analysing pre-collected 
data and wielding results that may not be possible or ethically or economi-
41 British Medical Association Board of Science. May 2006. Reporting adverse drug reactions: 
A guide for healthcare professionals. 2006.
42 Even where ADRs are reported, establishing that a particular drug is directly associated 
with a reaction is not a simple process, particularly where a patient may already be feeling 
ill and it might be difficult to differentiate between an ADR and a symptom of the patient’s 
illness.
43 P. Arlett and X. Kurz, “New approaches to strengthen pharmacovigilance”, Drug Discovery 
Today: Technologies 8(1) (2011), e15-e19.
44 E. Jackson, Law and the Regulation of Medicines, (Oxford: Hart Publishing, 2012) p. 99.
45 Supra note 6, p. 746. 
46 D. Light, “Bearing the Risks of Prescription Drugs” in: D. Light (ed.), The Risks of Prescription 
Drugs (Columbia University Press, 2010), pp. 1-39, at 7. 
47 E. Brook, D. Rosman and C. Holman, “Public good though data linkage: measuring 
research outputs from the Western Australian Data Linkage System”, Australian and New 
Zealand Journal of Public Health 32(1) (2008) 19-23.
48 Examples of routine data include mortality data cancer registries, hospital episodes data, 
and infectious disease data.
49 I.e. recall bias or interview bias, drop outs and completeness of response may be reduced’. 
A. Jönsson, “Drug-related morbidity and mortality: Pharmacoepidemiological aspects”, 
Linköping University Medical Dissertations No. 1030, Linköping (2007). Retrieved 23 
January 2014, www.diva-portal.org/smash/get/diva2:17207/FULLTEXT01. 
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cally viable in other settings such as clinical trials.50 Such studies can involve 
linking several different datasets. Numerous national and European initiatives 
are dedicated to maximising the research potential of reusing data for health 
research.51 Database studies are conducted throughout North America and 
Europe.52,53,54 
The major funding councils in the UK have collaborated on a £19 million 
funding call reflecting their appreciation of the importance of ‘the health 
research potential offered by linking electronic health records with other 
forms of routinely collected data and research datasets’.55 Indeed, the new 
UK-network of health linkage centres — the ‘Farr Institute’ — has been estab-
lished to ‘deliver high-quality, cutting-edge research linking electronic health 
data with other forms of research and routinely collected data’.56 Through data 
linkage, pharmacoepidemiological activities straddle questions of patient 
safety both immediately after a drug has been licensed, but also in the long-
term, where studies involve linkage of numerous data sets on large popula-
tions over significant time periods. Whilst major research funders appear to 
be moving in the direction of promoting and prioritising such research, the 
legislative regime(s) in this area are lagging behind, hampering these crucial 
activities, let us consider how.
4 Data Governance Regime: Losing Sight of Priorities
Although data linkage brings with it many advantages, including access to data 
which are already collected and which can be traced over long periods of time, 
50 W. Lowrance, Learning from Experience: Privacy and the Secondary Use of Data in Health 
Research (2002). (Report) The Nuffield Trust, p 6. 
51 P. Coorevits et al., “Electronic health records: new opportunities for clinical research”, 
Journal of Internal Medicine 274 (2013) 547–560.
52 A UK example is the Clinical Practice Research Datalink (CPRD) in the UK This was previ-
ously known as the General Practice Research Database. For more information see CPRD 
website. Retrieved 28 March 2014, www.cprd.com/intro.asp. 
53 Pharmo Record Linkage system as developed in the Netherlands. See Pharmo Institute for 
Outcomes Research. Retrieved 28 March 2014, www.pharmo.nl. 
54 Electronic Health Records for Clinical Research (EHR4CR) See EHR4CR website Retrieved 
7 April 2014, www.ehr4cr.eu.
55 Medical Research Council. 2012. “E-Health Informatics Research Centres Call.” Retrieved 
29 August 2012, www.mrc.ac.uk/Fundingopportunities/Calls/E-healthCentresCall/index.htm. 
56 For more information, see The Farr Institute, 2014. Retrieved 9 January 2014, www.farr 
institute.org. 
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reuse of data for data linkage purposes faces significant regulatory hurdles. 
This next section considers the regulatory hurdles currently inhibiting studies 
aimed at improving patient safety. Detailed accounts laying out the legislative 
landscape governing reuse of health data are recounted elsewhere.57 A sum-
mary of the problems with the current landscape as a whole sets the scene. 
4.1  Current Governance Regime
The key message from literature discussing governance of reuse of health 
data is clear: the current landscape is complex and unduly burdensome.58 
That the European Data Protection Directive (EuDPD) is open to interpreta-
tion by Member States (of the EU) perpetuates divergent approaches to data 
sharing across the European Union.59 The disproportionate procedures which 
researchers must navigate to access data are also well documented.60 A par-
ticular issue is the myriad, often repetitive and time-consuming approvals pro-
cedures which must be fulfilled prior to data access.61
The point is not that approvals procedures are unnecessary. On the con-
trary, ensuring that robust and proportionate legal and ethical standards are 
met both prior to and during the use of sensitive data is non-negotiable. What 
is crucial is that any standards which must be met — including data access and 
approval procedures — are appropriate to the level of perceived risk associ-
ated with a study. Equally, such standards should reflect the important goal of 
facilitating important health research which can contribute to patient safety, 
in line with the fundamental principle of ensuring the free flow of data — as 
provisioned in the EuDPD. It is paramount that legislation is not only opera-
57 G. Laurie and N. Sethi, “Information Governance of Use of Health-Related Data in Medical 
Research in Scotland: Current Practices and Future Scenarios.” (University of Edinburgh 
School of Law Working Paper No 2011/26, 2011).
58 Academy of Medical Sciences, Personal data for public good: using health information in 
medical research (2011); Academy of Medical Sciences, A new pathway for the regulation 
and governance of health research (2012); R. Thomas and T. Walport, Data Sharing Review 
Report (2008).
59 See for example: European Commission, “Commission Staff Working Paper Impact 
Assessment” Brussels, 25.01.2012, (SEC2012) 72 final (p. 13); N. Robinson et al., ‘Review of 
the European Data Protection Directive’ Technical Report Sponsored by the Information 
Commissioner’s Office, RAND Europe, (2009) ICO; Privacy in Research Ethics & Law 
(PRIVIREAL) Project. Retrieved 7 April 2014, www.privireal.org. 
60 Supra note 58.
61 M. Witham et al., “Construction of a linked health and social care database resource — 
lessons on process, content and culture”, Informatics for Health and Social Care (2014) 
(Epub ahead of print). Retrieved 5 April 2014, www.ncbi.nlm.nih.gov/pubmed/24650248. 
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tionalisable on a practical level, but that it enables data sharing in appropri-
ate contexts, rather than prohibiting sharing, especially when prohibitions are 
based on artificial and impractical distinctions made in law.
Let us consider, the dominant ‘consent or anonymise’ approach to current 
data reuse for health research in the UK.62 This is understood as implying that 
where patient consent cannot be obtained for using data for a research proj-
ect, then the data should be anonymised by default. Obtaining consent is not 
always possible or practical, particularly when one considers: 
. . . the cost of contacting hundreds of thousands, or even millions, of 
individuals. Or trying to reach them years after their health care encoun-
ter, when many may have relocated, some may have died, and some may 
not want to be reminded about an unpleasant of traumatic experience.63 
Notwithstanding, and although anonymisation of data can facilitate research, 
the process can also be problematic. It is said, for example, that complete ano-
nymisation or de-identification64 of data is in fact a myth,65 if not ‘very difficult 
to achieve in practice’.66 Moreover, ‘. . . the security of personal records in data-
bases cannot be guaranteed through anonymisation procedures’.67 This being 
said, anonymisation can still considerably diminish the likelihood of re-iden-
tification where this is the desired goal.68 Rather than discussing the impos-
sibility of re-identification of individuals, however, a more helpful and realistic 
framing of the discussion might be around likelihood69 of re-identification as 
opposed to judgements being made around possibility of re-identification; if 
we accept that anonymisation is a myth, then re-identification would always 
62 Academy of Medical Sciences, ‘Personal data for public good: using health information in 
medical research’ (2006).
63 K. El Emam and L. Arbuckle, Anonymizing Health Data, (USA: O’Reilly Media, 2013), at p. 2.
64 A. Narayanan and V. Schmatikov, ‘Myths and fallacies of “Personally Identifiable 
Information” ’, Communications of the ACM 53(6) (2010) 24-26.
65 P. Ohm, “Broken Promises of Privacy: Responding to the Surprising Failure of 
Anonymization”, UCLA Law Review, 57 (2010) 1701. U of Colorado Law Legal Studies 
Research Paper No. 9-12.
66 S. Fullerton et al., “Meeting the governance challenges of next-generation biorepository 
research”, Science Translational Medicine 2(15) (2010). 
67 The Royal Society 2012. ‘Science as an Open Enterprise’, The Royal Society Science Policy 
Centre report 02/12. 
68 See for example approach in UK Information Commissioner’s Office, “Anonymisation: 
Managing Data Protection Risk: Code of Practice”, (2012) p. 12.
69 Ibid.
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be possible, this offers a perfect example of an impractical categorisation 
within the legislative landscape. 
Indeed, eradicating the possibility of re-identification is not always the 
desired practical goal; an important aspect of pharmacoepidemiological and 
more general70 data linkage research is traceability of data. This enables lon-
gitudinal studies which track the effects of medication over a patient’s life-
time, drug safety issues may only arise after: a period of time, the development 
of new illnesses and/or the introduction of new medications to the patient. 
Re-identification of patients may be necessary ‘when clinically relevant infor-
mation arises during the course of a study which might have a direct impact 
on the treatment of a patient. In such cases, ethical principles demand re-
contacting and informing all relevant patients about the findings’.71 Further, 
traceability facilitates follow up studies of cohorts. Traceability implies that 
the patients are either identifiable, or that their data are pseudonymised, so 
that re-identification is possible. 
Pseudonymisation is one mechanism which does enable traceability whilst 
alleviating some concerns around using identifiable data. This is ‘the process of 
distinguishing individuals in a dataset by using a unique identifier which does 
not reveal their ‘real world’ identity.’72 It is considered a ‘powerful and flexible 
tool for privacy protection in databases’. It allows ‘linking data associated with 
the true individual, through the pseudo-IDs, irrespective of the collection time 
and place’.73 Pseudonymisation is one of several mechanisms which speak 
to current flexibilities around conducting data linkage74 however, even here, 
challenges exist. The extent to which pseudonymisation is (in)effective will 
depend upon the techniques used and the specific contexts of the research/
data use.75 The method may ‘not be adequate for many research purposes’.76 
70 K. Pommerening and M. Reng, “Secondary use of the EHR via pseudonymisation”, Studies 
in Health Technology and Informatics 103 (2004) 441-446.
71 L. Lo Iacono, “Multi-centric Universal Pseudonymisation for Secondary Use of the HER”, 
Studies in Health Technology and Informatics 126 (2007) 239-247, at p. 239.
72 Supra note 68, at p. 49.
73 R. Tinabo et al., “Anonymisation vs. Pseudonymisation: Which one is most Useful for both 
Privacy Protection and Usefulness of E-healthcare Data?” In Proc. IEEE 4th International 
Conference for Internet Technology and Secured Transactions (ICITST). (2009) Retrieved 
21 January 2014, ieeexplore.ieee.org/xpls/abs_all.jsp?arnumber=5402501&tag=1. 
74 Ibid. 
75 House of Commons Health Committee, ‘The Electronic Patient Record Sixth Report of 
Session 2006-07 Volume 1, at p. 91. HC 422-I; Iain Bourne, Information Commissioner’s 
Office (ICO) ‘The Complexities of Privacy and Anonymity XRDS: Crossroads’, The ACM 
Magazine for Students, Volume 20 Issue 1, Fall 2013 Pages 27-31, ACM New York, NY, USA.
76 Ibid. (at p. 91).
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Two important points can be made here. First, the lines between anony-
mous, pseudonymous and personal data are not clear cut. Current legislation 
unhelpfully assumes that these distinctions can be made easily, which is not the 
practical reality. Further, it is argued that we cannot and should not simply rely 
on technical processes to remedy the problems plaguing reuses of health data. 
Indeed, reliance on technical processes in turn gives rise to confusion around 
definitions and around which techniques are acceptable to satisfy thresholds 
of ‘anonymisation’, ‘pseudonymisation’ and relatedly, to what counts as ‘per-
sonal data’.77 We need to consider the purposes, contexts78 and value of reus-
ing health data. It has been suggested that the confusing landscape governing 
data reuse, which makes difficult demands on researchers and data custodi-
ans in negotiating with ill-defined terms, has led to a culture of caution, with 
fear of sanctions for data sharing which may actually not be inappropriate.79 
The focus here is on the effects of data protection legislation on conducting 
pharmacoepidemiological — and more broadly — health research through 
data reuse. However, it is also important to acknowledge that cultural attitudes 
and practices towards data reuse must play an undeniable role in how data are 
used,80 but equally, the law plays a significant role in shaping the regulatory 
landscape. Consequently, a clearer, flexible and practicable framing of data 
reuse is required.
Another solution which does accommodate consideration of the purposes 
of reuse involves taking principled proportionate approaches to governance, 
as I have argued elsewhere.81 One example of taking such an approach is via 
authorisation, whereby a proxy decision-maker in the form of an individual 
or body can authorise a linkage. However, pre-existing mechanisms within 
the current landscape which facilitate data linkage are limited. Further, the 
77 UK Information Commissioner’s Office, ‘Proposed draft EU General Data Protection 
Regulation and ‘law enforcement’ Directive. Comparative analysis of the European 
Commission text and the European Parliament’s LIBE (civil liberties) Committee amend-
ments.’ Retrieved 7 April 2014, http://ico.org.uk/news/blog/2013/~/media/documents/
library/Data_Protection/Research_and_reports/Proposed-draft-EU-General-Data-
Regulation-and-law-enforcement-Directive-20140124.pdf.
78 Supra note 68.
79 Ibid.
80 See for example: Journal of American Medical Informatics Association, doi:10.1136/
amiajnl-2012-001575.
81 See G. Laurie and N. Sethi, “Towards Principles-Based Approaches to Governance of 
Health-related Research using Personal Data”, European Journal of Risk Regulation 
1 (2013) 43-57 N. Sethi and G. Laurie, “Delivering proportionate governance in the era of 
eHealth: Making linkage and privacy work together”, Medical Law International 13(2-3) 
(2013) 168-204.
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flexibility currently offered by pseudonymisation, which facilitates many sig-
nificant studies based on reuse of health data is put at risk in the proposed 
Data Protection Regulation.82 
4.2 Proposed Legislative Reform: What Is Around The Corner?
We have briefly considered above the current regulatory landscape governing 
the reuse of data for research, concluding that a regulatory approach which 
better promotes sharing data in appropriate circumstances is needed. The 
EuDPD was drafted at a time when the use of the Internet to share and collate 
data was in a nascent stage.83 Internet use has proliferated, alongside globali-
sation, technical advances and the numerous internet-related privacy scan-
dals in news headlines. Issues of transfer of data to countries outside the EU 
have also emerged.84 It has become clear that the current Directive is no lon-
ger fit for purpose.85 Legislative reform is underway and rather than adopting 
another directive, a regulation has been proposed to replace the ‘patchwork of 
national laws with a single set of rules’.86 A robust analysis of the proposed leg-
islation is not offered here, given that full agreement has not yet been reached 
on the final text. Rather, this section considers which direction the current text 
(which has just been approved by the European Parliament) might steer data 
reuse towards, concluding that if the European Council approves the current 
text, the end point for such research could be even worse than the current 
unacceptable situation. 
82 Wellcome Trust. May 2013. ‘Impact of the draft European Data Protection Regulation and 
proposed amendments from the rapporteur of the LIBE committee on scientific research’ 
Retrieved 29 March 2014www.wellcome.ac.uk/stellent/groups/corporatesite/@policy_
communications/documents/web_document/wtvm054713.pdf. 
83 European Parliament, ‘Q&A on EU data protection reform’, 4 March 2014. Retrieved 29 
March 2014,www.europarl.europa.eu/pdfs/news/expert/background/20130502BKG07917/
20130502BKG07917_en.pdf. 
84 For discussion see: M. Birnhack, “The EU Data Protection Directive: An engine of a global 
regime”, Computer Law & Security Review 24(6) (2008) 508–520; P. Schwartz, “European 
Data Protection Law and Restrictions on International Data Flow”, 80 Iowa Law Review 80 
(1995) 471.
85 R. Wong, ‘The Shape of Things to Come: Swedish Developments on the Protection of 
Privacy’, SCRIPTed 2(1) (2005) 98-113.
86 European Parliament News. 2014. QA on Data Protection Reform, 4 March 2014. Retrieved 
17 March 2014, www.europarl.europa.eu/news/en/news-room/content/20130502BKG 
07917/html/QA-on-EU-data-protection-reform.
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The initial draft proposal of the General Data Protection Regulation was 
advanced by the European Commission in January 2012.87 Two years and sev-
eral delays later, it has still not been adopted; unsurprising when we consider 
the myriad stakeholder concerns involved. The drafters have been charged 
with the unenviable task of legislating on a wide range of data protection 
issues. Whilst the proposed Regulation could help to clarify issues around the 
processing of personal data for the purposes of monitoring drug safety pre-
marketing,88 it is argued here that an opportunity is being missed in improving 
how data reuse in post-marketing pharmacoepidemiological studies and wider 
health research — also integral for patient safety — can take place. The lead 
Committee on Civil Liberties, Justice and Home Affairs (LIBE) voted to adopt 
recommendations from Rapporteur Albrecht (the Albrecht Report)89 which 
proposed numerous amendments to the Regulation. Certain  amendments, 
which were proposed in January 2013, have raised significant concerns amongst 
the research community.90,91
The European Parliament has approved the amended text which appears to 
be missing out on the opportunity of realigning the due regard for one of the 
87 European Commission, Proposal for a Regulation of the European Parliament and of the 
Council on the protection of individuals with regard to the processing of personal data 
and on the free movement of such data (General Data Protection Regulation), Brussels 
25.01.12 COM (2012) 11 final 2012/0011 (COD). 
88 Directive 2010/84/EU and Regulation (EU) No 1235/2010 impose obligations on pharma-
ceutical companies to report adverse events however it has not always been clear how 
those legislation interact with the EU Data Protection Directive. The Draft Data Protection 
Regulation specifies that health data may be processed for ‘ensuring high standards of 
quality and safety for medicinal products and product safety’ thus potentially providing a 
clearer legislative base for the use of personal data and the retention of data for research. 
See: International Pharmaceutical Privacy Consortium. March 2012. ‘Comments in 
response to the call for evidence on EU Data Protection Proposals.’ Retrieved 7 April 2014, 
www.pharmaprivacy.org/download/IPPC%20Comments%20UK%20Consultation%20
on%20Proposed%20Data%20Protection%20Regulation.pdf. 
89 Rapporteur Jan Philipp Albrecht, Committee on Civil Liberties, Justice and Home Affairs, 
Draft Report on the proposal for a regulation of the European Parliament and of the 
Council on the protection of individual with regard to the processing of personal data and 
on the free movement of such data (General Data Protection Regulation) COM (2012) 
0011 — C7-0025/2012 — 2012/0011(COD)).
90 M. Ploem and K. Stronks, “Proposed EU data protection regulation is a threat to medical 
research” (Editorial), British Medical Journal 346 (2013)f3534; and supra note 82.
91 R. Fears et al., “Data protection regulation and the promotion of health research: getting 
the balance right”, Quarterly Journal of Medicine 107 (2014) 3–5.
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fundamental principles upon which the EuDPD was originally founded; the 
free flow of data which corresponds to promoting sharing data in appropriate 
circumstances. The draft Regulation includes clear acknowledgement that:
The centrepiece of existing EU legislation on personal data protection, 
Directive 95/46/EC3, was adopted in 1995 with two objectives in mind: 
to protect the fundamental right to data protection and to guarantee the 
free flow of personal data between Member States.92
Further, ‘[t]he current framework remains sound as far as its objectives and 
principles are concerned’,93 references to achieving the dual objectives of data 
protection and ensuring the free flow of data are made throughout the draft 
Regulation. Indeed, the very wording of the Regulation title is ‘Regulation of 
the European Parliament and of the Council on the protection of individu-
als with regard to the processing of personal data and on the free movement 
of such data’.94 It is argued here that despite such explicit articulations of the 
dual goals of protecting privacy and promoting free movement of data, the 
clearly important role of protecting individual privacy rights distracts from 
the equally important goal of facilitating data sharing, in this case, facilitating 
the reuse of data for patient safety and health research. Let us consider in more 
detail the relevant provisions and amendments to the draft regulation, (which 
emanated from the Albrecht Report) to demonstrate how this is so. 
The Albrecht Report proposed (and Parliament agreed) that Article 81 of the 
original draft Regulation be revised to read as follows:
Processing of personal data concerning health which is necessary for his-
torical, statistical or scientific research purposes, shall be permitted only 
with the consent of the data subject,95 and shall be subject to the condi-
tions and safeguards referred to in Article 83.96 
92 Supra note 87 (Explanatory Memorandum, Para. 1).
93 Ibid.
94 Emphasis added.
95 Emphasis added.
96 European Parliament, Committee on Civil Liberties, Justice and Home Affairs, 
2012/0011(COD), Draft Report on the proposal for a regulation of the European Parliament 
and of the Council on the protection of individual with regard to the processing of per-
sonal data and on the free movement of such data (General Data Protection Regulation) 
(COM (2012)0011 — C7-0025/2012 — 2012/0011(COD)) Amendment 327 Proposal for a 
regulation Article 81 — paragraph 2, Hereafter referred to as ‘Albrecht Report’.
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It is not clear to this author precisely where pharmacoepidemiological studies 
which aim to investigate long-term post-marketing effects of drugs fits in the 
legislation. If such studies are viewed as fitting under ‘scientific research pur-
poses’ as many data linkage studies are, then the implications of this amend-
ment would be that research using identifiable data where consent has not 
been obtained will be prevented. 
Article 7 of the Albrecht Report requires consent to be “specific, informed 
and explicit”. The (im)practicalities around obtaining consent97 and the over-
reliance of consent as a panacea to all potential privacy concerns have been 
discussed at length elsewhere,98 but clear practical hurdles include resources 
such as time and budget to facilitate obtaining consent, if even possible. These 
barriers could prevent many studies going ahead.99 
With regards to pseudonymisation, we considered above that this process 
provides at least some flexibility within the current landscape however there 
is a lack of sufficient clarity with regards to whether pseudonymised data 
will fall under the scope of ‘personal data.’100 This being said, a recent Art 29 
DPWP Opinion on anonymisation has raised the bar with regards to anonymi-
sation and suggests that pseudonymised data ‘stays inside the scope of the 
legal regime of data protection’.101 If the new regulation text is approved by 
the European Council, then “[t]he inclusion of pseudonymised data within the 
scope of ‘personal data’ could dramatically increase the regulatory burden on 
research.”102 This will place even tighter restrictions upon the extent to which 
these data can be reused. The UK Information Commissioner’s Office noted 
that if personal data is to be defined so as to include pseudonymised data, then 
97 E. Regidor, “The use of personal data from medical records and biological materials: ethi-
cal perspectives and the basis for legal restrictions in health research”, Social Science and 
Medicine (54) (2004) 1975-1894, at p. 1976; P. Furness and L. Nicholson, “Obtaining Explicit 
Consent for the Use of Archival Tissue Samples: Practical Issues”, Journal of Medical Ethics 
20 (2004) 561.
98 G. Laurie, “Evidence of support for biobanking practices”, British Medical Journal 337 
(2008) 337; G. Laurie and E. Postan, “Rhetoric or Reality: What is the legal status of the 
consent form in health-related research?”, Medical Law Review 21(3) (2013) 371-414. 
99 Supra note 82, Supra note 90, M. Andersen and H. Storm, “Cancer registration, public 
health and the reform of the European data protection framework: Abandoning or 
improving European public health research?”, European Journal of Cancer (2013) (Epub 
ahead of print).
100 Supra note 77. 
101 Article 29 Data Protection Working Party, Opinion 05/2014 on Anonymisation Techniques, 
0829/14/EN WP216, adopted 10 April 2014.
102 Supra note 82. 
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‘. . . it is important to be clear that a wide definition plus all the associated rules 
in full would not work in practice.’103 Another Albrecht amendment proposed 
that pseudonymised health data could be used without consent but only if the 
threshold of ‘exceptionally high public interest’ is met.104 Indeed, under Article 
42 of the original draft Regulation: ‘historical, statistical and scientific research 
purposes’ were included as legitimate reasons for ‘derogating from the prohibi-
tion of processing sensitive categories of data’.105 The drafters of the Albrecht 
Report state: 
Processing of sensitive data for historical, statistical and scientific research 
purposes is not as urgent or compelling as public health or social protec-
tion. Consequently, there is no need to introduce an exception which 
would put them on the same level as the other listed justifications.106
The clear value statement included in the quote above is problematic given 
the significant contributions pharmacoepidemiological studies make towards 
patient safety. Again, exactly where such research sits with regards to ‘scientific 
research’ or ‘public health’ is questionable and it is argued that the distinction, 
based on ‘urgency’ between the different uses of data is unhelpful and can lead 
to prohibiting important activities. 
Thus far, we have considered why availability of health data is crucial for 
patient safety, as guaranteed by pharmacoepidemiological research. We have 
outlined some reasons why the current data protection regime is sub-optimal 
with regards to facilitating such activities. Key points which have emerged are 
that researchers can use different technical methods for privacy protection 
but none is free from issues: particularly given the fact that the more infor-
mation which is joined together from different sources, the more the likeli-
hood of identifiability will increase,107 as with ‘jigsaw’ techniques.108 Further, 
there is uncertainty and variance in practice around pseudonymisation 
techniques.109 Such observations serve as examples of how unhelpful it can be 
to focus solely on categorizing types of data and types of use when the ultimate 
103 Supra note 77. 
104 Albrecht Report, Amendment 328, Proposal for a regulation Article 81 — paragraph 2 a 
(new).
105 Draft Regulation Article 42.
106 Albrecht Report, Amendment 27 Proposal for a regulation Recital 42.
107 M. Gymrek et al., “Identifying personal genomes by surname inference”, Science 339 (2013) 
321-324.
108 Supra note 64. 
109 Supra note 61. 
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goal of such studies is to ensure patient safety. Pharmacoepidemiology as we 
have considered, speaks to patient safety at different levels, not only in the 
context of pre-marketing surveillance of drug reactions, but also in the wider 
context of health research studies which focus on drug effects in wide popula-
tions over a sustained period of time, but nonetheless contribute significantly 
towards patient safety. We have briefly considered above the effects which the 
amended draft regulation might have on data reuse in health research if the 
European Council follows the Parliament in approving the text.
It has been considered that proposed changes to the European frame-
work may be particularly detrimental to realising the potential of data reuse 
in health research, especially if pharmacoepidemiological studies fit under 
‘scientific research purposes’, if pseudonymisation is brought to fit under the 
scope of personal data and if explicit consent is required prior to data reuse 
for such data. 
5 Reorienting the Research Path 
This final section suggests that a reorientation of how the reuse of data is pri-
oritised within data protection legislation could improve the current situation. 
A role is envisaged for the law as an enabler of data sharing, where this is for 
scientifically and ethically robust reuse of patient data not only for pharmaco-
epidemiological research, but for wider health research. Two means of enact-
ing this role are posited here: the first is in the form of the establishment of a 
dedicated Working Party on data reuse and the second in the form of bespoke 
legislation specifically aimed at data reuse for research. An overview of each is 
offered alongside reasons why these options might be considered.
5.1  The Establishment of a Dedicated Working Party on Data Reuse
Issues relating to reuse of health data for research are currently considered at 
an EU level by the Article 29 Data Protection Working Party (Art 29 DPWP). 
The Party was established in 1996 alongside the EuDPD. The Art 29 DPWP 
comprises of: ‘a representative of the supervisory authority (ies) designated 
by each EU country; a representative of the authority(ies) established for the 
EU institutions and bodies; a representative of the European Commission.’110 
The Art 29 DPWP has delivered several opinions relating to data reuse. Thus 
110 European Commission, Article 29 Working Party. Retrieved 29 March 2014, ec.europa.eu/
justice/data-protection/article-29/index_en.htm. 
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far, notable opinions relate to consent111 and the roles of data controllers and 
processors.112 
It is suggested here that establishing a dedicated Working Party, with a simi-
lar composition to Art 29 DPWP, but which is committed to considering purely 
those issues arising out of reuse of data for health related research, would 
offer significant benefits. First and foremost, such a group could deliver opin-
ions which specifically respond to the challenges and concerns encountered 
by key actors who are reliant upon gaining access to health data for research 
purposes. Such opinions would also aid data custodians who are charged with 
the responsibility of determining when to share data. Under Article 30 of the 
EuDPD, Art 29 DPWP is charged with the following tasks:
1. (a) examine any question covering the application of the national mea-
sures adopted under this Directive in order to contribute to the uniform 
application of such measures; 
2. (b) give the Commission an opinion on the level of protection in the 
Community and in third countries; 
3. (c) advise the Commission on any proposed amendment of this Directive, 
on any additional or specific measures to safeguard the rights and free-
doms of natural persons with regard to the processing of personal data 
and on any other proposed Community measures affecting such rights 
and freedoms; 
4. (d) give an opinion on codes of conduct drawn up at Community level.113
It is proposed here that a new Data Reuse for Health Research Working Party 
would be charged with the above tasks as they relate to the new Data Protection 
Regulation should it be adopted. The Working Party could also be charged 
with clarifying whether pharmacoepidemiological studies are included in 
this sphere. Additional tasks of the Working Party would include: (a) drafting 
European level Guiding Principles of data reuse for health research, and (b) 
consulting on the potential for drafting new dedicated legislation governing 
health data reuse in research. Both of these tasks are considered next.
111 Article 29 Data Protection Working Party, Opinion 15/2011 on the definition of consent, 
Adopted 13 July 2011.
112 Article 29 Data Protection Working Party, Opinion 1/2010 on the concepts of ‘controller’ 
and ‘processor’, 00264/10/EN, WP 169, adopted 16 February 2010.
113 Article 30 Directive 95/46/EC of the European Parliament and of the Council of 
24 October 1995 on the protection of individuals with regard to the processing of personal 
data and on the free movement of such data.
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5.1.1  Guiding Principles and Best Practice
Introducing a key set of guiding principles, supported by examples of best 
practice context could provide many benefits for researchers and data custo-
dians alike. Principles should be seen as fundamental starting points to guide 
deliberation and action.114 Principle-based approaches in this context are 
‘the use of broadly-stated objectives, standards and values by which individu-
als and institutions should conduct themselves when using data for research 
purposes.’115 The merits of principle-based approaches in the health research 
context have been discussed elsewhere.116 However, in order to help orient 
readers to the value which guiding principles could bring in this context, key 
points relating to adopting principle-based approaches to decision making are 
recounted here. 
As we have considered, the complex legislative landscape is difficult to 
navigate. Overarching principles can offer clear articulations not only to 
guide action on everyday practices, but also to offer a set of standards against 
which conduct should be measured. This has been the approach adopted in 
the Scottish context of data reuse for health research by the Scottish Health 
Informatics Programme (SHIP).117 This Scotland-wide project which is dedi-
cated to maximising the research potential of data reuse of electronic health 
records has adopted a set of Guiding Principles and Best Practice, subsequently 
endorsed by the Scottish Information Commissioner’s Office and adopted by 
the Scottish Government for its Data Linkage Framework.118
A set of Guiding Principles can provide decision-makers across the EU with 
‘broad-based values and commonly-agreed objectives to determine through 
deliberation and reflection what action best fits in accordance with the par-
ticular value(s) advanced.119 Having a pre-determined, clear set of values can 
compensate for the gaps in the law where a clear course of action for the situ-
ation at hand is not offered. It is impossible to legislate on every perceivable 
eventuality; principles offer flexibility and guidance where provisions are not 
provided within the law.120 Principles can help to provide transparency to 
114 See T. Honderich (ed.), The Oxford Companion to Philosophy (Oxford: Oxford University 
Press, 1995), p. 719.
115 Supra note 81.
116 Ibid. 
117 For more see SHIP website. Retrieved 31 March 2014, www.scot-ship.ac.uk. 
118 See scotland.gov.uk/Topics/Statistics/datalinkageframework. Retrieved 7 April 2014.
119 Supra note 81.
120 Ibid.
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decision-makers and to data subjects alike, about the standards against which 
conduct will be measured.
The very process of drafting key principles and consulting key stakeholders 
across the EU can be of value in itself. This iterative process has the poten-
tial to uncover previously overlooked challenges to data reuse, which none-
theless require attention and clarification. A Principle-based approach could 
also tend to the current gaps which pharmacoepidemiological research falls 
into, it would promote sharing in appropriate contexts rather than forcing the 
research community to guess whether their activities (for example pharmaco-
epidemiological studies) and the associated data fit within certain provisions. 
Common principles can engender ‘mutual respect between all stakeholders 
and participants’.121 
It is necessary also to acknowledge some weaknesses of principle-based 
approaches. Principles have often been criticised for being vague and abstract 
in nature,122 leaving significant scope for interpretation,123 and a lack of 
prescription can give rise to confusion about how to interpret and apply 
 principles.124 As Knoppers et al. note when considering principles: ‘. . . discus-
sion on the nature of such principles and their procedural translation in differ-
ent contexts will necessarily vary.’ However it is argued here that the benefits of 
offering over-arching principles at the European level which have been men-
tioned above outweigh the limitations associated with principles. 
5.1.2 Consultation On New Legislation
The merits of new legislation are discussed in more detail below. Conducting a 
consultation on what this new legislation should and should not include could 
be one of the key tasks for the Working Party. It will be best placed, having 
drafted guiding principles and having dealt with queries from Member States 
(of the EU), to draft an informed legislative proposal for wider consultation.
121 B. Knoppers et al., ‘Towards a data sharing Code of Conduct for international genomic 
research’, Genome Medicine 46(3) (2011) 4.
122 L. Sama and V. Shoaf, “Reconciling Rules and Principles: An Ethics-Based Approach to 
Corporate Governance”, Journal of Business Ethics 58 (2005), p. 1; and supra note 84 
(Towards Principles).
123 See for example, J. Harris, ‘In praise of unprincipled ethics’, Journal of Medical Ethics 29 (5) 
(2003) 303-306. 
124 See for example: K. Danner Clouser and B. Gert, ‘A Critique of Principlism’, Journal of 
Medical Philosophy 15 (1990) 219-236; W. Muirhead, ‘When four principles are too many: 
bloodgate, integrity and an action-guiding model of ethical decision making in clinical 
practice’, Journal of Medical Ethics 38 (2012) 195-196.
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5.2  New and Dedicated Legislation Governing Data Reuse
This next suggestion for reorienting the landscape moves one step further: 
introducing legislation specifically on the reuse of health data for research is 
proposed. As mentioned above, reuse of data for health research is prolifer-
ating, and will continue to do so as we move towards establishing new and 
strengthening pre-existing e-health infrastructures. Rather than relying upon 
building-in provisions for reuse of data within a larger regulation such as the 
proposed Data Protection Regulation, it is worthwhile considering introducing 
legislation which from the outset, is designed to legislate on health data reuse 
in the research context. It is argued here that having clear legislative articu-
lations dedicated to the specific context of data reuse is a necessary starting 
point and cultural change is unlikely to occur without explicit reference to the 
need for sharing such data.
It has already been acknowledged above that revising, let alone drafting 
European-level legislation is by no means an easy feat, as exemplified by the 
duration of the drafting process for revisions to the current Directive. However, 
it is questionable whether this would be any more of an undertaking than the 
current ambitious task of revising the EuDPD as it stands. This proposal is for 
a clear and coherent Directive/Regulation which at its core, strives to enable 
data sharing activities to secure patient safety, and which acknowledges that 
this can occur in the context of wider pharmacoepidemiological research 
which necessitates reuse of patient data which does not only take place under 
pharmacovigilance activities. 
Introducing new legislation is akin to taking a rule-based approach to 
regulation.125 This can offer more concreteness in comparison to principles and 
prescriptive126 articulations of conduct required from activities related to data 
reuse for research. In turn, dedicated legislation could provide a greater degree 
of certainty for researchers and custodians than the current legislative ‘patch-
work’ which must be interpreted. As we considered above, the wide scope of 
the current Directive contains but a few mere exemptions which directly relate 
to the processing of data for health research purposes and lack clarity around 
key concepts such as pseudonymisation and personal data. Like principle-
based approaches, rule-based approaches also have some  shortcomings, most 
125 For discussion on rule-based and principle-based regulation, see: A. Kern and N. Moloney, 
Law Reform and Financial Markets (Cheltenham: Edward Elgar Publishing: 2011) at p. 8; 
J. Black, The Rise, Fall and Fate of Principles Based Regulation (LSE Law Society and 
Economy Working Papers 17/2010 2010). 
126 J. Braithwaite, “Rules and Principles: A Theory of Legal Certainty”, Australian Journal of 
Legal Philosophy 27 (2002).
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notably in their rigidity and the impossibility of anticipating and thus legislat-
ing for absolutely every possible eventuality.127
It is proposed here that a dedicated working party, new legislation, in tan-
dem with a set of clear guiding principles might be considered as options to 
improve the status quo. Such a dual-approach would allow more prescriptive 
legislation and overarching principles to tend to the respective short-falls of 
each other. In particular, rules can offer clear and definitive guidance where 
possible, and principles can offer flexibility for those issues which require 
more (and inevitable) discretion on the part of decision-makers. As has been 
acknowledged earlier in this article, there are some cultural issues around shar-
ing which legislation alone cannot overcome alone, however including clear 
articulations within legislation that enables and promotes important reuse of 
data for patient safety can act as a driver for cultural change in attitudes to and 
confidence around data sharing and use.
5.3  Openness of Data: Additional Consideration
The recently approved Clinical Trials Regulation128 attempts to encourage more 
transparency and openness of data. The new Regulation will require detailed 
and plain language summaries of clinical trial data to be posted on a data-
base set up and run by the European Medicines Agency, these summaries and 
final trial reports will also be freely and publicly accessible on a central data-
base. The major UK funding councils have recently begun explicitly to push 
the Open Access agenda whereby data and results must be available to the 
research community who may wish to verify research findings. This necessar-
ily implicates data sharing and some funding is conditional upon these terms 
being fulfilled. It is worthwhile considering whether and if so, how European 
data protection legislation will progress towards promoting transparency and 
openness in the same way that the new Clinical Trials Regulation aspires to. 
It is also worth asking whether and if so, how the research community will 
be guided in terms of adhering to Open Access requirements whilst simulta-
neously negotiating with the current ill-fitting Directive. It also remains to be 
seen how the demands of a future Data Protection Regulation will sit alongside 
aspirations to create ‘a second open science revolution.’129
127 S. Arjoon, “Striking a Balance Between Rules and Principles-based Approaches for 
Effective Governance: A Risk-based Approach”, Journal of Business Ethics 68 (2006) 53 
et seq., at p. 65.
128 Regulation (EU) No . . . /2014 of the European Parliament and of the Council on clinical 
trials on medicinal products for human use, and repealing Directive 2001/20/EC. 
129 Supra note 68. 
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6  Conclusion
This article has highlighted the clear and pressing need for a shift in data 
protection legislation to explicitly recognise the value in and importance of 
data reuse in research. Neither the current EuDPD nor the proposed Albrecht 
amendments to the Draft Regulation adequately reflect this need. The impor-
tant principle of promoting sharing is overshadowed by the need to protect 
privacy. Compromising privacy is by no means advocated or suggested by this 
author. It is clear that ‘data sharing is not in opposition to privacy and should 
be conducted in a responsible way such that it does not infringe on the privacy 
rights of individuals and groups’.130 The key message here is that there is a need 
to realign the current legislative regime in order to enable responsible reuse of 
health data for research.
One can sympathise with those charged with drafting the regulation, 
which must extend across the European Union and given the array of stake-
holders and data-related activities which must be regulated. This formidable 
legislative undertaking does not however abrogate the fact that important 
activities may be hampered significantly, a concern reflected amongst the 
research community in their consideration of the proposed amendments.131 
Pharmacoepidemiological studies may particularly suffer if proposals are 
adopted to consider pseudonymised data as ‘personal data’, to require consent, 
and where this is not possible, to require exceptionally high public interest 
thresholds must be satisfied. Due urgency is not being granted to facilitating 
pharmacoepidemiological studies and those studies relying on data reuse 
for health research more broadly. The legislative landscape must reorientate 
towards promoting and enabling reuse of health data for research.
We must acknowledge that the law can take significant steps in reshaping the 
regulatory landscape, but cultural attitudes and practices towards data reuse 
play an undeniable role and can be equally difficult to change.132 It is argued 
here that having clear legislative articulations dedicated to the specific con-
text of data reuse is a necessary starting point and cultural change is unlikely 
to occur without explicit reference to the need for sharing data for reuse in 
health research. The key step to liberating the research community from the 
shadow of uncertainty around data sharing is introducing clear and coherent 
legislation which explicitly recognises the value of data linkage upfront and 
130 Supra note 29. 
131 Supra notes 82 and 90.
132 See for example: Journal of the American Medical Informatics Association, doi:10.1136/
amiajnl-2012-001575.
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encourages ethically and legally robust data sharing. This legislation should be 
coupled with the establishment of a dedicated working party tasked with con-
sidering issues specific to the context of data reuse in health research and with 
establishing guiding principles, which at the very least, could provide timely, 
meaningful and practical signposts on the specific issues related to reuse of 
data for health research. At best, these solutions could help us get back on 
track to realising the potential which data reuse has for securing patient safety.
